Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.
Valuation and Earnings
This table compares Oramed Pharmaceuticals and BioMarin Pharmaceutical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $2.00 million | 98.59 | $64.05 million | $4.12 | 1.15 |
| BioMarin Pharmaceutical | $3.22 billion | 3.84 | $348.90 million | $0.37 | 172.81 |
Profitability
This table compares Oramed Pharmaceuticals and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -5.17% | -4.54% |
| BioMarin Pharmaceutical | 2.14% | 5.32% | 3.69% |
Analyst Ratings
This is a summary of recent ratings and price targets for Oramed Pharmaceuticals and BioMarin Pharmaceutical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 1 | 2.70 |
BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 39.46%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Oramed Pharmaceuticals.
Insider & Institutional Ownership
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Oramed Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
Summary
BioMarin Pharmaceutical beats Oramed Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
